Skip to main content

Table 4 AR therapeutic management by the interviewed physicians

From: Physicians’ prescribing behaviour and clinical practice patterns for allergic rhinitis management in Italy

Item Whole sample Allergologists ENTs GPs p-value
N = 2823 N = 909 N = 606 N = 1308
Main prescription drivers < 0.001
 Effective on all AR symptoms 1533 (54.3%) 501 (55.1%) 335 (55.2%) 697 (53.2%)  
 Quick symptom relief 1352 (47.8%) 429 (47.1%) 287 (47.3%) 636 (48.6%)  
 Increased patient adherence 959 (33.9%) 255 (28%) 242 (39.9%) 462 (35.3%)  
 Sustained efficacy 921 (32.6%) 307 (33.7%) 189 (31.1%) 425 (32.4%)  
 Few/no side effects 911 (32.2%) 303 (33.3%) 164 (27%) 444 (33.9%)  
 Effective with few drugs 849 (30%) 290 (31.9%) 198 (32.6%) 361 (27.5%)  
 Easy to take 848 (30%) 228 (25%) 192 (31.6%) 428 (32.7%)  
 Supported by scientific literature 470 (16.6%) 216 (23.7%) 127 (20.9%) 127 (9.7%)  
 Affordable price 379 (13.4%) 137 (15%) 70 (11.5%) 172 (13.1%)  
 Refundable 246 (8.7%) 60 (6.6%) 14 (2.3%) 172 (13.1%)  
Follow-up timing < 0.001
 < 12 months 86 (3%) 36 (4%) 24 (4%) 26 (2%)  
 Every 12 months 1166 (41%) 427 (47%) 242 (40%) 497 (38%)  
 Every 6 months 722 (26%) 272 (30%) 188 (31%) 262 (20%)  
 < 6 months 865 (31%) 172 (19%) 157 (26%) 536 (41%)  
Treatment regimen < 0.001
 Monotherapy 1170 (41.4%) 303 (33.3%) 246 (40.5%) 621 (47.4%)  
 Polytherapy 1653 (59.6%) 606 (66.7%) 360 (59.4%) 687 (52.5%)  
  1. Data are expressed as number of patients (%). Chi squared test was used to investigate differences in the observed frequencies across specialty area